SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Spyre Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Development Fee | – | – | – | – | – | – | – | – | – | – | – | $2.33M | – | – |
| Development fee and royalty | – | – | – | – | – | – | $0 | $0 | $0 | $688.00K | $886.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Spyre Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.